Spreading false information? - The EU Commission obliges the Pharmaceutical Company to rebuttal
Global pharmaceutical company Vifor may have to make misleading statements regarding the safety of a competitor product's security and retract them. The European Commission specifically ordered Vifor to send a brief clarification message to numerous healthcare professionals via email, mail, and in person meetings, according to the authority. The reason being, Vifor may have spread misleading information about the safety of a medication from Danish competitor Pharmacosmos.
This could potentially allow Vifor to abuse its dominant position on the German market, the Commission added. Therefore, the Commission obliged Vifor to publish a statement on its website and in leading medical scientific journals - in addition, Pharmacosmos must be allowed to use this statement in consultations with doctors.
Both companies produce preparations used to treat iron deficiency intravenously. Both Ferinject (Vifor) and Monofer (Pharmacosmos) are high-dosed iron preparations and are used, for instance, when other medications that are typically taken orally do not work or cannot be administered.
- Vifor, a prominent Pharmaceutical company, is based in Europe and is under scrutiny for making misleading statements about a rival product's safety from their Danish competitor, Pharmacosmos, within the pharmaceutical industry.
- The European Commission, located in Brussels, has issued a directive to Vifor, requiring them to provide a counter-representation to numerous healthcare professionals, addressing their misleading claims about the safety of Pharmacosmos' competitor product.
- The Pharmaceutical industry in Europe is closely monitoring this situation, as it could potentially affect the market competition between Vifor and Pharmacosmos, with Vifor holding a dominant position in Germany.
- As part of the European Commission's ruling, Vifor must publish a statement on their website and in leading medical scientific journals, allowing Pharmacosmos to utilize this information in consultations with doctors.
- This incident highlights the importance of maintaining transparency and accuracy in the pharmaceutical industry, with competitors and regulatory bodies closely watching to ensure compliance with rules and regulations.
